Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test improve treatment for a common cause of high blood pressure?

NCT ID NCT06108427

Disease control Sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to dose a common blood pressure medication (MRA) for people with primary aldosteronism, a condition where the body makes too much aldosterone. Doctors will use a blood test for renin, a hormone, to guide dosing. The goal is to see if this leads to better control and fewer side effects. About 58 adults with newly diagnosed primary aldosteronism will be randomly assigned to either renin-guided or standard care for 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mineralocorticoid receptor antagonists (MRA)
What this could lead to
If successful, this approach could make MRA treatment safer and more effective for people with primary aldosteronism, reducing side effects while controlling blood pressure.
What could go wrong
This is a small feasibility study, so results may not apply to everyone. The renin-guided method may not improve outcomes or could be harder to implement in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 58 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Over 18 years of age * Diagnosis of PA, in accordance with clinical guidelines and local practice * Suppressed plasma renin prior to treatment initiation (plasma renin concentration \>15 mIU/L or \>10 ng/L, or plasma renin activity \>1 ng/mL/h) * Planned long-term treatment with mineralocorticoid receptor antagonist Exclusion Criteria: * Prior use of mineralocorticoid receptor antagonist or any potassium-sparing diuretics in the past 3 months * Known intolerance or contraindication to mineralocorticoid receptor antagonist treatment * eGFR \< 30 ml/min/1.73m2 (past 3 months) * Baseline serum potassium above \> 4.8 mmol/L (past 3 months) * Deemed medically unsafe to stop medications for the initiation of MRA as monotherapy * Pregnancy or breastfeeding * Participation in another study that is likely to affect renin or BP levels * Inability to provide consent due to cognitive impairment and/or language barrier.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary aldosteronism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary aldosteronism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital du Sacré-Coeur de Montréal

    RECRUITING

    Montreal, Quebec, H4J1C5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.